Search results
Sparrow Pharmaceuticals Announces Cushing’s Syndrome Treatment Results
Exec Edge via Yahoo Finance· 2 days agoBy Daniella Parra Sparrow Pharmaceuticals said its HSD-1 inhibitor, clofutriben (SPI-62), normalized...
Meditating with headband that tracks brain activity may improve surgical recovery in patients with ...
Medical Xpress· 4 days agoPatients with Cushing's syndrome who are recovering from surgery and wear a headband that tracks...
Crinetics Unveils 'Stunning' Results In Highly Anticipated Study
Investor's Business Daily· 4 days agoCrinetics unveiled "stunning" results Monday from a study of a drug that tamps down on levels of a...
Hormonal 'Ups and Downs' Are Normal—but These 8 Symptoms May Point to a True Imbalance
Well and Good· 1 day agoYou've likely heard that it's the culprit for a variety of vague health symptoms, or that "balancing...
Science explains why bearded ladies are so common – but history has treated them cruelly
The Telegraph via Yahoo News· 5 days ago‘You should be women,” says a terrified Banquo when he and Macbeth meet the witches conjuring spells...
Crinetics shares maintain price target, Overweight rating on positive trial data By Investing.com
Investing.com· 3 days agoOn Tuesday, Piper Sandler maintained its Overweight rating and $97.00 stock price target for...
Corcept (CORT) Up 24.5% Since Last Earnings Report: Can It Continue?
Zacks via Yahoo Finance· 7 days agoRevenues increased 39% year over year to $146.8 million. The figure beat the Zacks Consensus...
Corcept shares target raised on positive trial data, holds Buy rating By Investing.com
Investing.com· 3 days agoTuesday, Truist Securities has increased its price target for Corcept Therapeutics (NASDAQ:CORT) to...
Corcept Therapeutics director Swisher sells $66.5k in stock By Investing.com
Investing.com· 2 days agoCorcept Therapeutics Inc. (NASDAQ:CORT) director Daniel N. Swisher Jr. has recently sold shares of...
This Small-Cap Biotech Is on the Cusp of a Breakout
TheStreet.com· 4 days agoWith upcoming partnerships and innovation programs, a relatively unknown stock could soon gain more attention from the market. Breadth is still running...